Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96

One important prerequisite for developing a therapeutic monoclonal antibody is to evaluate its in vivo efficacy. We tested the therapeutic potential of an anti-CD96 antibody alone or in combination with an anti-PD-1 antibody in a mouse colon cancer model. Early anti-PD-1 treatment significantly decr...

Descripción completa

Detalles Bibliográficos
Autores principales: Boch, Christina, Reschke, Markus, Igney, Frederik, Maier, Peter, Müller, Philipp, Danklmaier, Sarah, Das, Krishna, Hofer, Tamara, Wollmann, Guido, Rist, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495994/
https://www.ncbi.nlm.nih.gov/pubmed/36140247
http://dx.doi.org/10.3390/biomedicines10092146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495994/
https://www.ncbi.nlm.nih.gov/pubmed/36140247
http://dx.doi.org/10.3390/biomedicines10092146

Ejemplares similares